0000318989-16-000092.txt : 20160506
0000318989-16-000092.hdr.sgml : 20160506
20160506145932
ACCESSION NUMBER: 0000318989-16-000092
CONFORMED SUBMISSION TYPE: SC 13G
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20160506
DATE AS OF CHANGE: 20160506
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Dimension Therapeutics, Inc.
CENTRAL INDEX KEY: 0001592288
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463942159
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-89163
FILM NUMBER: 161627464
BUSINESS ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-401-0011
MAIL ADDRESS:
STREET 1: 840 MEMORIAL DRIVE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: FIL Ltd
CENTRAL INDEX KEY: 0000318989
STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000]
IRS NUMBER: 000000000
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: SC 13G
BUSINESS ADDRESS:
STREET 1: P.O. BOX H.M. 670
CITY: HAMILTON
STATE: D0
ZIP: 00000
BUSINESS PHONE: 6175637100
MAIL ADDRESS:
STREET 1: P.O. BOX H.M. 670
CITY: HAMILTON
STATE: D0
ZIP: 00000
FORMER COMPANY:
FORMER CONFORMED NAME: FIL LTD
DATE OF NAME CHANGE: 20080213
FORMER COMPANY:
FORMER CONFORMED NAME: FIDELITY INTERNATIONAL LTD
DATE OF NAME CHANGE: 19920929
SC 13G
1
20160512_6059000113GFIL74869.txt
SCHEDULE 13G
SCHEDULE 13G
Amendment No. 0
DIMENSION THERAPEUTICS INC
COMMON STOCK
Cusip #25433V105
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
Cusip #25433V105
Item 1: Reporting Person - FIL Limited
Item 2: (a) [ ]
(b) [ ]
Item 4: Bermuda
Item 5: 2,066,979
Item 6: 0
Item 7: 2,066,979
Item 8: 0
Item 9: 2,066,979
Item 11: 8.261%
Item 12: FI
Cusip #25433V105
Item 1: Reporting Person - Pandanus Partners, L.P.
Item 2: (a) [ ]
(b) [ ]
Item 4: Delaware
Item 5: 0
Item 6: 0
Item 7: 2,066,979
Item 8: 0
Item 9: 2,066,979
Item 11: 8.261%
Item 12: PN
Cusip #25433V105
Item 1: Reporting Person - Pandanus Associates, Inc.
Item 2: (a) [ ]
(b) [ ]
Item 4: Delaware
Item 5: 0
Item 6: 0
Item 7: 2,066,979
Item 8: 0
Item 9: 2,066,979
Item 11: 8.261%
Item 12: CO
Item 1(a). Name of Issuer:
DIMENSION THERAPEUTICS INC
Item 1(b). Address of Issuer's Principal Executive Offices:
840 MEMORIAL DRIVE
4TH FLOOR
CAMBRIDGE, MA 02139
USA
Item 2(a). Name of Person Filing:
FIL Limited
Item 2(b). Address or Principal Business Office or, if None,
Residence:
Pembroke Hall, 42 Crow Lane, Hamilton, Bermuda,
HM19
Item 2(c). Citizenship:
Not applicable
Item 2(d). Title of Class of Securities:
COMMON STOCK
Item 2(e). CUSIP Number:
25433V105
Item 3. Not Applicable
Item 4. Ownership
(a) Amount Beneficially Owned: 2,066,979
(b) Percent of Class: 8.261%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
2,066,979
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the
disposition of: 2,066,979
(iv) shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certifications.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect. By signing below I certify that, to the best of my knowledge and
belief, the foreign regulatory scheme applicable to FIL Limited and its
various non-U.S. investment management subsidiaries included on this
Schedule 13G is substantially comparable to the regulatory scheme
applicable to the functionally equivalent U.S. institutions. I also
undertake to furnish to the Commission staff, upon request, information
that would otherwise be disclosed in a Schedule 13D.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
May 6, 2016
Date
/s/ Marc R. Bryant
Signature
Marc R. Bryant
Duly authorized under Power of Attorney effective as of September 16,
2015, by and on behalf of FIL Limited and its direct and indirect
subsidiaries*
* This power of attorney is incorporated herein by reference to
Exhibit B to the Schedule 13G filed by FIL Limited on January 11, 2016,
accession number: 0000318989-16-000061.
Exhibit A
Pandanus Partners, L.P. ("Pandanus") owns shares of FIL
Limited ("FIL") voting stock. While the percentage of total voting power
represented by these shares of FIL voting stock may fluctuate as a result
of changes in the total number of shares of FIL voting stock outstanding
from time to time, it normally represents more than 25% and less than 50%
of the total votes which may be cast by all holders of FIL voting stock.
Pandanus Associates, Inc. ("PAI") acts as general partner of Pandanus.
Pandanus is owned by trusts for the benefit of members of the family of
Edward C. Johnson 3d but disclaims that any such member is a beneficial
owner of the securities reported on this Schedule 13G.
This filing reflects the securities beneficially owned, or
that may be deemed to be beneficially owned, by FIL, certain of its
subsidiaries and affiliates, and other companies (collectively, the "FIL
Reporters"). This filing does not reflect securities, if any, beneficially
owned by certain other companies whose beneficial ownership of securities
is disaggregated from that of the FIL Reporters in accordance with
Securities and Exchange Commission Release No. 34-39538 (January 12, 1998).
RULE 13d-1(k)(1) AGREEMENT
The undersigned persons, on May 6, 2016, agree and consent
to the joint filing on their behalf of this Schedule 13G in connection with
their beneficial ownership of the COMMON STOCK of DIMENSION THERAPEUTICS
INC at May 2, 2016.
FIL Limited
By /s/ Marc R. Bryant
Marc R. Bryant
Duly authorized under Power of Attorney effective as of September 16,
2015, by and on behalf of FIL Limited and its direct and indirect
subsidiaries*
Pandanus Partners, L.P.
By /s/ Marc R. Bryant
Marc R. Bryant
Duly authorized under Power of Attorney effective as of September 16,
2015, by Pandanus Associates, Inc. on behalf of Pandanus Partners, L.P.*
Pandanus Associates, Inc.
By /s/ Marc R. Bryant
Marc R. Bryant
Duly authorized under Power of Attorney effective as of September 16,
2015, by and on behalf of Pandanus Associates, Inc.*
* This power of attorney is incorporated herein by reference to
Exhibit B to the Schedule 13G filed by FIL Limited on January 11, 2016,
accession number: 0000318989-16-000061.